Product details
The CJC-1295 + Ipamorelin combination is one of the most-requested GH-axis blends in the catalog and one of the most-cited dual-pathway formulations in research and academic workflows. The two peptides act on parallel signaling pathways that converge on somatotroph GH release: CJC-1295 (no DAC, the Modified GRF 1-29 form) is a GHRH-receptor agonist mimicking the hypothalamic GHRH input, while Ipamorelin is a selective GHSR (ghrelin receptor) agonist mimicking the alternative ghrelin-pathway input. The dual-pathway combination produces GH-release magnitudes substantially larger than either component alone at comparable individual doses, the synergy is the entire rationale for the combination.
Peptuno supplies the CJC-1295 + Ipamorelin blend as a co-lyophilized vial at ≥99.0% HPLC purity for each component. The standard ratio is 1:1 by mass (5+5 mg in a 10 mg vial); custom ratios (2+5, 5+10, 10+10) and larger total fills are available through Peptuno's custom-synthesis programme. Co-lyophilization is preferred over solution-phase mixing because both components are short-half-life peptides where ratio stability matters operationally and the co-lyophilized form locks the ratio at the lyophilization step. The release packet certifies both component purities individually plus the actual ratio in the released vial.
FAQ
- Why is the CJC-1295 + Ipamorelin combination considered the canonical GH-axis blend?
- The combination works because the two components engage different receptors that converge on the same target cell type. CJC-1295 (no DAC) activates the GHRH receptor on anterior-pituitary somatotrophs; Ipamorelin activates the GHSR (ghrelin) receptor on the same cells. The two signaling cascades reinforce rather than compete, producing GH-release magnitudes substantially larger than either alone, typically 4-5× larger acute GH pulse at comparable individual doses. The combination is the canonical dual-pathway GH-axis reagent set, supplied as a co-lyophilised vial so the ratio is locked at the lyophilisation step rather than mixed in solution by the buyer.
- Can I substitute Sermorelin or Tesamorelin for CJC-1295 in this blend?
- Yes, all three are GHRH-receptor agonists and produce mechanistically equivalent dual-pathway combinations when paired with Ipamorelin. The Tesamorelin + Ipamorelin blend (tesa-ipa-blend SKU) is supplied at a 10+5 mg ratio reflecting the higher mass-equivalent dosing typical for Tesamorelin. Sermorelin + Ipamorelin is less common in commercial blends because Sermorelin's shorter half-life is less well-matched to Ipamorelin's pharmacokinetics. The CJC-1295 (no DAC) + Ipamorelin pairing remains the most-requested combination because the half-life profiles complement each other best.
Certificate of Analysis (COA)
The per-lot COA for this product will appear here.